Crop Science sales fell 9.1% YoY, and Pharmaceuticals saw mixed results with Nubeqa and Kerendia growing, but Xarelto declining 23.8% due to generics. Bayer's strategic transformation under CEO ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

However, the decline of its blockbuster blood thinner Xarelto, due to patent expiration, remains a significant challenge. Despite Bayer’s low valuation—its shares trade at just 3.9 times forward ...

Bayer is also seeing some success with newer drugs such as cancer medicine Nubeqa. It needs these to offset rising generic competition for its best-selling anti-clotting medication Xarelto ...

Bayer declined to comment ... but bestselling blood-thinner Xarelto is in decline as it loses patent protection. Analysts at brokerage BMO Capital Markets said in a note that even though the ...

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide). The ...

They should help offset the sales decline of blockbuster blood thinner Xarelto, which is facing patent expiry. The erosion this quarter was “more rapid” than anticipated, JPMorgan analyst Richard ...

Bayer has established a strong presence in emerging markets and is well positioned to benefit from these fast-growing regions. Generic Xarelto entry in various territories over the near term ...

Bayer declined to comment. Bayer’s warning that earnings ... but bestselling blood-thinner Xarelto is in decline as it loses patent protection. Analysts at brokerage BMO Capital Markets said in a note ...

Bayer — which focuses on agriculture ... such as rising generic competition for its blockbuster blood-thinning drug Xarelto and regulatory challenges at its crop protection business.

Stifel Nicolaus analyst Andreas Heine has maintained their neutral stance on 0P6S stock, giving a Hold rating yesterday. Don't Miss our Black Friday Offers: Andreas Heine’s rating is based on a ...